The reactivity pattern of HMGB1 autoantibodies in systemic lupus erythematosus is associated with longer disease duration with the linker region between the DNA-binding B- box and the C-terminal tail being widely recognised
This study reveals that patients with systemic lupus erythematosus exhibit broad anti-HMGB1 autoantibody reactivity, particularly targeting the Linker 2 region between the B-box and C-terminal tail, a pattern associated with longer disease duration and observed in both patients and healthy controls.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the human body, the immune system acts as a vigilant defense force, constantly scanning for invaders like bacteria and viruses. To do this, it produces Y-shaped proteins called antibodies that latch onto specific foreign targets, marking them for destruction. However, in a condition known as systemic lupus erythematosus, this system malfunctions. Instead of focusing only on external threats, the immune system loses its ability to distinguish friend from foe and begins attacking the body's own tissues. This self-destruction is driven by a chaotic mix of signals and proteins released when cells are stressed or die. One such protein, which scientists call HMGB1, normally lives safely inside the nucleus of a cell, helping to organize DNA. When a cell is damaged, this protein escapes into the surrounding tissue, where it acts as a distress signal, shouting to the immune system that something is wrong. In people with lupus, this signal seems to go on too loud and too long, keeping the immune system in a state of high alert.
Researchers have long known that people with lupus produce antibodies that mistakenly target this HMGB1 protein, but the exact nature of this mistake has remained a mystery. It was unclear whether these antibodies were attacking the protein as a whole or zeroing in on specific parts of it. This distinction matters because different parts of the protein have different jobs; some parts trigger inflammation, while others might calm it down. If the antibodies are hitting the wrong spot, they could be making the disease worse, or perhaps they are trying to stop the inflammation. A team of scientists from Norway and Sweden set out to map exactly where these antibodies were binding. They gathered blood samples from 210 patients with lupus and 100 healthy individuals, looking for antibodies that recognized HMGB1. They tested the blood against the full protein and against smaller, isolated pieces of it, much like checking if a key fits a whole lock or just one specific pin inside it.
The results showed that people with lupus had significantly higher levels of these antibodies than the healthy group, and these antibodies were not picky; they tended to recognize multiple parts of the protein at once. However, the amount of antibody did not seem to rise and fall with the daily severity of the patient's symptoms. Instead, the researchers found a quiet but steady connection between the presence of these antibodies and how long a person had lived with the disease. The longer someone had lupus, the more likely they were to have a broad, multi-targeted antibody response. This suggests that the immune system's confusion regarding this protein is not a sudden flare-up but a slow, accumulating change over years.
To see exactly which parts of the protein were being targeted, the team used a high-resolution technique that tested the blood against thousands of tiny, overlapping snippets of the HMGB1 sequence. They discovered that the antibodies were not primarily attacking the main, well-known sections of the protein that were previously thought to be the most important. Instead, the antibodies overwhelmingly latched onto a specific stretch of the protein that acts as a connector between two major sections. This connector region, located between the middle and the end of the protein, was the most frequently recognized spot in both the lupus patients and the healthy controls. While healthy people mostly stopped their attack at this connector, the lupus patients often extended their recognition to include the tail end of the protein as well.
This broader attack, reaching beyond the connector to the very end of the protein, was seen more often in patients who had been sick for a longer time. The study did not find evidence that these antibodies were driving the immediate, day-to-day inflammation of the disease, nor did it prove that they were harmful or helpful. What the researchers did establish is a clear pattern: as lupus persists, the immune system's antibodies become more widespread in their targets, moving from a single focus to a broader assault on the protein's structure. This detailed map of where the antibodies bind provides a new foundation for future research, helping scientists understand whether these specific targets can be used to track the disease's history or to develop treatments that might calm the immune system's mistaken alarm.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.